Funding round
AdvanCell Series D
AdvanCell, which works in radiopharmaceutical development and manufacturing in Sydney, raised $315M in a Series D round announced on 15 Jul 2026, led by Ally Bridge Group and Alpha Wave Global. 19 firms took part. It is AdvanCell's third venture round on record; the one before was a Series C in Feb 2025.
$315M
Amount raised
Not disclosed
Post-money valuation
19
Investors
2 leads
Valuation
What this round says about the price
AdvanCell did not disclose a valuation in this round. It came 17 months after AdvanCell's Series C. It is 62% of the $505M AdvanCell has raised in the venture rounds on record. No later venture round is on record for AdvanCell.
Investors
Who put money in
Ally Bridge Group and Alpha Wave Global led the round with 17 other firms.
Lead investors
- backs 37 venture-backed companies new investor
- Alpha Wave Global backs 78 venture-backed companies new investor
Also in the round
- Bain Capital Life Sciences new investor
- Fidelity Management & Research Company new investor
- T. Rowe Price new investor
- Eventide Asset Management new investor
- backs 16 venture-backed companies new investor
- Morningside new investor
- Eli Lilly and Company new investor
- backs 46 venture-backed companies new investor
- Sanofi Ventures new investor
- backs 19 venture-backed companies new investor
- backs 14 venture-backed companies new investor
- backs 9 venture-backed companies new investor
- backs 17 venture-backed companies new investor
- backs 23 venture-backed companies new investor
- backs 57 venture-backed companies new investor
- new investor
- backs 10 venture-backed companies new investor
Joined the board: Andrew Lam (Ally Bridge Group) and Nik Economopoulos (Alpha Wave).
Use of proceeds
What the money is for
According to the announcement, the money goes to product development, geographic expansion, scaling operations and working capital.
- Product development
- Geographic expansion
- Scaling operations
- Working capital
Comparable rounds
How it compares
14 Series D rounds in Pharmaceutical Products within a year either side disclosed an amount; the median was $62M, and this round was 5.1 times the median. The closest in time, other companies' Series D rounds in Pharmaceutical Products:
| Company | Announced | Amount | Post-money | Led by |
|---|---|---|---|---|
| Abcuro Pharmaceutical Products | 18 Aug 2026 | $66M | not disclosed | New Leaf Venture Partners |
| Pharmaceutical Products | 11 Jun 2026 | $47M | not disclosed | 太平医疗健康基金 and 上海科创集团 |
| Pharmaceutical Products | 18 May 2026 | $150M | not disclosed | Vivo Capital |
| Pharmaceutical Products | 19 Oct 2026 | $135M | not disclosed | M Ventures and Revelation Partners |
| Pharmaceutical Products | 9 Apr 2026 | $50M | not disclosed | Boehringer Ingelheim |
| Pharmaceutical Products | 25 Mar 2026 | $32M | not disclosed | Elev8 Venture Partners |
| Pharmaceutical Products | 5 Feb 2026 | $130M | not disclosed | Frazier Life Sciences and Venrock |
| Pharmaceutical Products | 22 Jan 2026 | $287M | not disclosed | not named |
Sources
Where this comes from
Reported by 8 sources.
Questions
Frequently asked
How much did AdvanCell raise in its Series D round?
AdvanCell raised $315M in its Series D round, announced in Jul 2026.
Who led AdvanCell's Series D round?
Ally Bridge Group and Alpha Wave Global led it, with Bain Capital Life Sciences, Fidelity Management & Research Company, T. Rowe Price, Eventide Asset Management and Velocity Capital and 12 more.
What was AdvanCell's valuation at the Series D round?
It was not disclosed.
How does it compare with other Series D rounds in Pharmaceutical Products?
14 Series D rounds in Pharmaceutical Products within a year either side disclosed an amount; the median was $62M, and this round was 5.1 times the median.